Superworth

ImmunityBio IBRX

Biotechnology, Healthcare
$7.95
−4.10%
Market cap
$8.4B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
50.8×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$165.8M
+193% on a year ago
Net margin
n/m
outside −100% to 100%
Free cash flow yield
−3.4%

ImmunityBio trades at 50.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $165.8M over the last twelve months, up 193% on a year earlier.

Charts

Financials

Income statement for IBRX, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$82K−31%$139K+90%$40K−89%$1M+2454%$6.1M+7346%$7.6M+5333%$16.5M+41193%$26.4M+2424%$32.1M+425%$38.3M+407%$44.2M+168%$51.2M+94%
Cost of revenue$0$0$0$0$0$0$58K$136K$177K$382K$238K+310%$298K+119%
Gross profit$82K$139K$40K$1M+2454%$6.1M+7346%$7.6M+5333%$16.5M+41048%$26.3M+2411%$31.9M+422%$37.9M+402%$44M+167%$50.9M+94%
R&D$48.4M−32%$51.5M−11%$53.4M−33%$51.1M−4%$50.4M+4%$35.2M−32%$48.2M−10%$55.2M+8%$51.2M+2%$63.9M+81%$68M+41%$60.8M+10%
SG&A$31.8M+65%$33.1M+26%$41.9M+28%$49.3M+54%$35.9M+13%$41.7M+26%$32.7M−22%$42.3M−14%$36.3M+1%$38.7M−7%$45.8M+40%$51.8M+22%
−$80.1M−12%−$85.4M+1%−$95.2M−15%−$99.3M+17%−$80.3M+0%−$69.4M−19%−$64.4M−32%−$71.3M−28%−$55.6M−31%−$64.7M−7%−$69.8M+8%−$61.7M−14%
Interest expense$35M+109%$31.9M+12%$29.5M−1%$29.8M−8%$29.3M−16%$26.1M−18%$15.3M−48%$15.5M−48%$15.3M−48%$14.9M−43%$14.6M−5%$14.1M−9%
Pre-tax income−$95.6M−14%−$233.5M+116%−$134.1M+15%−$134.6M−3%−$85.8M−10%−$59.2M−75%−$129.9M−3%−$92.3M−31%−$67.3M−22%−$62.1M+5%−$632.8M+387%−$230.4M+150%
$0−$40K$0$0$0$0−$234K$269K−$35K−$135K$9K$0
Net income−$95.6M−14%−$233.4M+116%−$134.1M+15%−$134.6M−2%−$85.7M−10%−$59.2M−75%−$129.6M−3%−$92.6M−31%−$67.3M−22%−$61.9M+5%−$632.8M+388%−$230.4M+149%
−$0.19−32%−$0.35+30%−$0.20−26%−$0.20−38%−$0.14−26%−$0.08−77%−$0.15−25%−$0.10−50%−$0.07−50%−$0.06−25%−$0.62+313%−$0.22+120%
498.4M+25%667.8M+66%672.8M+57%686.9M+57%698M+40%733.2M+10%853.2M+27%888.2M+29%946.6M+36%989.7M+35%1B+20%1.1B+18%

Revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

Gross profit: 13 periods, Q2 FY23 to Q2 FY26: not printed by the filing, worked out from its own lines.

R&D: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

Operating income: Q1 FY14: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY14: 6 months less the 3 months printed beside them.

EPS, diluted: 8 periods, Q1 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY14: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Biotechnology nearest ImmunityBio's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
IBRXImmunityBio$8.4Bn/mn/an/m50.8×+193%n/m
KRYSKrystal Biotech$8.8B37.1×42.5×n/m19.9×+23%54.8%
RGENRepligen$9.8B237×123×n/m12.4×+16%5.3%
TECHBIO-TECHNE$11.4B63.2×62.0×n/m9.4×−0%15.0%
HALOHalozyme Therapeutics$14.6B38.5×21.3×n/m8.8×+41%24.9%
NBIXNeurocrine Biosciences$14.8B21.3×42.6×n/m4.4×+34%20.9%
EXELExelixis$17.4B22.1×22.7×n/m7.1×+9%35.3%
ALNYAlnylam Pharmaceuticals$21.2B26.7×68.2×18.9×4.4×+95%16.8%
INCYIncyte$24.3B15.3×36.5×51.3×4.2×+27%27.7%
UTHRUnited Therapeutics$25.9B21.6×14.2×22.6×8.2×+2%41.6%
ADMAAdma Biologics$2.5B15.8×21.3×n/m4.8×+8%33.0%
Peer median$14.7B24.4×39.5×22.6×7.7×+20%26.3%

More on ImmunityBio

Each number over time

Where it ranks

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .